top of page
Jul 21, 2023
PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
Apr 20, 2023
PsyBio Announces Closing of Third Tranche of Private Placement
Apr 6, 2023
PsyBio Announces Panel Participation on NextGen Psychedelics at Benzinga Cannabis Capital Conference
Mar 13, 2023
PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit
Jan 17, 2023
A PsyBio Therapeutics Corp. (CVE:PSYB) insider increased their holdings last year
Jan 13, 2023
PsyBio Announces Closing of Second Tranche of Private Placement
Jan 10, 2023
PsyBio Announces Appointment of Ian Wisenberg to Board of Directors
Jan 5, 2023
PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update
Dec 8, 2022
PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT
Dec 6, 2022
PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
Dec 1, 2022
PsyBio Therapeutics Announces Non-Brokered Private Placement Financing
Nov 29, 2022
PsyBio Therapeutics Reports Third Quarter 2022 Financial Results
bottom of page